← Back to Clinical Trials
Recruiting NCT04634643

Pathogenesis of Pediatric Nonalcoholic Fatty Liver Disease (NAFLD)

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition NAFLD
Sponsor Yale University
Study Type OBSERVATIONAL
Phase N/A
Enrollment 260
Sex ALL
Min Age 12 Years
Max Age 18 Years
Start Date 2021-06-28
Completion 2026-01-30
Interventions
Usual diet and physical activity

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The main aim of the study is to discover the mechanisms underlying the pathophysiology of NAFLD in obese youth.

Eligibility Criteria

Inclusion Criteria: * Good general health, taking no medication on a chronic basis; * age 12 to 18 years, in puberty (girls and boys: Tanner stage II-V); * BMI \>85th for obese cohort; Exclusion Criteria: * Baseline creatinine \>1.0 mg; pregnancy; * the presence of endocrinopathies (e.g. Cushing syndrome); * cardiac or pulmonary or other significant chronic illness; * adolescents with a psychiatric disorder or with substance abuse; * monogenic obesity syndromes; * use of drugs affecting intrahepatic fat content (e.g.; liraglutide, fish oil, etc.).

Related Trials

VIEW ON CLINICALTRIALS.GOV ↗ MORE NAFLD TRIALS
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}